Demographic, clinical, and patient-reported outcome data from two global, Phase 3 trials of chronic cough

This pooled analysis examined the medical histories and clinical characteristics of 2044 adult patients with refractory or unexplained chronic cough enrolled in the Phase 3 COUGH-1 and COUGH-2 trials. In both studies, objective 24-hour cough frequency was calculated from recordings captured using the Vitalograph VitaloJAK device.